UBS Group
CDMO

UBS Group’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History

UBS Group’s Portfolio CDMO Stock Details CDMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-794,861
Closed -$9.82M – 11013
2024
Q4 		$9.82M Buy
794,861
+609,423
+329% +$6.98M ﹤0.01% 3067
2024
Q3 		$2.11M Buy
185,438
+8,017
+5% +$80.5K ﹤0.01% 3938
2024
Q2 		$1.27M Sell
177,421
-149,195
-46% -$1.14M ﹤0.01% 4193
2024
Q1 		$2.19M Buy
326,616
+65,558
+25% +$451K ﹤0.01% 3859
2023
Q4 		$1.7M Buy
261,058
+207,004
+383% +$1.33M ﹤0.01% 3992
2023
Q3 		$510K Sell
54,054
-32,607
-38% -$392K ﹤0.01% 4637
2023
Q2 		$1.21M Buy
86,661
+11,197
+15% +$191K ﹤0.01% 4053
2023
Q1 		$1.42M Sell
75,464
-128,073
-63% -$2.1M ﹤0.01% 3778
2022
Q4 		$2.8M Buy
203,537
+178,974
+729% +$2.74M ﹤0.01% 3041
2022
Q3 		$470K Sell
24,563
-13,119
-35% -$239K ﹤0.01% 4393
2022
Q2 		$575K Sell
37,682
-170,262
-82% -$2.52M ﹤0.01% 4163
2022
Q1 		$4.24M Buy
207,944
+47,565
+30% +$969K ﹤0.01% 2695
2021
Q4 		$4.68M Buy
160,379
+27,385
+21% +$784K ﹤0.01% 2891
2021
Q3 		$2.87M Buy
132,994
+57,420
+76% +$1.39M ﹤0.01% 3243
2021
Q2 		$1.94M Buy
75,574
+43,923
+139% +$938K ﹤0.01% 3606
2021
Q1 		$577K Buy
31,651
+23,194
+274% +$385K ﹤0.01% 4760
2020
Q4 		$98K Buy
+8,457
New +$77.3K ﹤0.01% 5702
2020
Q3 		– Sell
-17,852
Closed -$117K – 8496
2020
Q2 		$117K Sell
17,852
-15,921
-47% -$88.9K ﹤0.01% 5181
2020
Q1 		$173K Sell
33,773
-38,807
-53% -$235K ﹤0.01% 4836
2019
Q4 		$557K Buy
72,580
+37,927
+109% +$221K ﹤0.01% 4746
2019
Q3 		$184K Buy
34,653
+16,114
+87% +$100K ﹤0.01% 5308
2019
Q2 		$104K Buy
18,539
+8,168
+79% +$33.7K ﹤0.01% 5353
2019
Q1 		$44K Sell
10,371
-27,470
-73% -$112K ﹤0.01% 5648
2018
Q4 		$155K Buy
37,841
+7,403
+24% +$38.6K ﹤0.01% 5157
2018
Q3 		$209K Buy
30,438
+8,686
+40% +$51.5K ﹤0.01% 5025
2018
Q2 		$86K Buy
21,752
+18,895
+661% +$65.5K ﹤0.01% 5565
2018
Q1 		$8K Sell
2,857
-20
-0.7% -$62 ﹤0.01% 7019
2017
Q4 		$11K Hold
2,877
– – ﹤0.01% 6972
2017
Q3 		$9K Sell
2,877
-2,170
-43% -$8.15K ﹤0.01% 6963
2017
Q2 		$21K Buy
5,047
+420
+9% +$1.72K ﹤0.01% 6268
2017
Q1 		$21K Buy
4,627
+1,726
+59% +$5.78K ﹤0.01% 6112
2016
Q4 		$6K Hold
2,901
– – ﹤0.01% 7172
2016
Q3 		$9K Sell
2,901
-5,444
-65% -$14.6K ﹤0.01% 6858
2016
Q2 		$21K Buy
8,345
+2,394
+40% +$6.67K ﹤0.01% 6274
2016
Q1 		$18K Sell
5,951
-3,113
-34% -$16.7K ﹤0.01% 6298
2015
Q4 		$75K Buy
9,064
+3,835
+73% +$31K ﹤0.01% 5454
2015
Q3 		$37K Sell
5,229
-2,214
-30% -$18.5K ﹤0.01% 6095
2015
Q2 		$68K Sell
7,443
-416
-5% -$4K ﹤0.01% 5725
2015
Q1 		$74K Sell
7,859
-4,747
-38% -$45.7K ﹤0.01% 5672
2014
Q4 		$123K Buy
+12,606
New +$127K ﹤0.01% 5491

Other funds holding CDMO

TCWM
Total Clarity Wealth Management St. Charles, Illinois $515M AUM 27.37% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group's CDMO Position: Q1 2025 in Review

UBS Group sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q1 2025, closing a stake of 794,861 shares — an estimated $9.82M sold.

UBS Group first reported a position in CDMO in Q4 2014 and held it in 40 quarters. The position peaked at $9.82M in Q4 2024. 2 funds tracked by Wall St. Rank hold CDMO as of Q1 2025.

  • UBS Group reported no remaining Avid Bioservices, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • UBS Group sold 794,861 Avid Bioservices, Inc. Common Stock shares in Q1 2025, an estimated $9.82M.
  • UBS Group first reported a position in Avid Bioservices, Inc. Common Stock in Q4 2014 and held it in 40 quarters.
  • UBS Group's Avid Bioservices, Inc. Common Stock position peaked at $9.82M in Q4 2024.
  • 2 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q1 2025.

Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.